Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987817 · ClinicalTrials.gov registry record · Phase 2
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
A Phase 2 study of Peanut Allergy, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 8
- Study locations
NCT01987817: Completed Phase 2 study of Peanut Allergy, sponsored by Aimmune Therapeutics.
NCT01987817 is a Phase 2 study of Peanut Allergy that has completed, run by Aimmune Therapeutics. The registered enrollment target is 56 participants, below the 210-participant average among 13 other Peanut Allergy trials with a reported enrollment target (73% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01987817, a Phase 2 study of Peanut Allergy, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
Primary Outcome
The primary endpoint was the percentage of subjects who achieved desensitization, as determined by tolerating at least 300 mg (443 mg cumulative) of peanut protein at the Exit Double Blind Placebo Controlled Food Challenge (DBPCFC) with no more than mild symptoms (i.e., desensitization responders)
Conditions Studied
Interventions
- BIOLOGICAL AR101 powder provided in capsules
- BIOLOGICAL Placebo powder provided in capsules
Study Locations (8)
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- UC San Diego - San Diego
Massachusetts
- Boston Children's Hospital - Boston
New York
- Mount Sinai Medical Center - New York
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Children's Medical Center Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-02-06 |
| Est. Completion | 2015-01-07 |
| Phase | Phase 2 |
What the finished NCT01987817 record still lists
NCT01987817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 210-participant average among 13 other Peanut Allergy trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which AR101 powder provided in capsules is the first listed.
NCT01987817 lists 8 locations in 8 states (Arkansas, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01987817 about?
NCT01987817 is a clinical study titled "Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT". This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
What is the current status of trial NCT01987817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2014-02-06. Estimated completion is 2015-01-07.
What conditions does trial NCT01987817 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT01987817?
The interventions under investigation include: AR101 powder provided in capsules (BIOLOGICAL), Placebo powder provided in capsules (BIOLOGICAL).
Who is sponsoring clinical trial NCT01987817?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01987817 being conducted?
This trial has 8 study locations across Arkansas, California, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01987817's enrollment target sits among peer trials
56 9th of 13 higher than 5 of 13 other Peanut Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peanut Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
COMPLETED · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI